Placental α-Microglobulin-1 in Vaginal Secretions of Women with Evidence of Preterm Labor

Abstract Objective To evaluate the presence of placental α-microglobulin-1 (PAMG-1) in vaginal secretions in women with symptoms of preterm labor and assess its use as a predictor of preterm birth. Study Design A prospective cohort study of women between 16 and 34 weeks of gestation with symptoms of preterm labor and intact membranes was conducted. The presence of PAMG-1 was determined using a commercially available kit (AmniSure, AmniSure International LLC, Boston, MA). Results A total of 100 women were enrolled, of which 86 had outcome data available. PAMG-1 was detected in 19/86 (22.1%) subjects. These women were more likely to deliver within 7 days than those without PAMG-1 detected (6/19 [31.6%] vs. 5/67 [7.5%]; odds ratio 5.6; 95% confidence interval 1.5–21.6). These findings persisted after adjusting for potential confounders. The sensitivity was 54.6%, specificity was 82.7%, positive predictive value was 31.6%, and the negative predictive was 92.5%. Conclusion The presence of PAMG-1 is associated with an increased likelihood of delivery within 7 days.

[1]  T. Nikolova,et al.  Evaluation of a novel placental alpha microglobulin-1 (PAMG-1) test to predict spontaneous preterm delivery , 2014, Journal of perinatal medicine.

[2]  C. Foster,et al.  Fetal fibronectin as a biomarker of preterm labor: a review of the literature and advances in its clinical use. , 2014, Biomarkers in medicine.

[3]  R. Romero,et al.  The clinical significance of a positive Amnisure test in women with preterm labor and intact membranes , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[4]  Ibrahim Anwar Abdelazim,et al.  Placental alpha microglobulin-1 (AmniSure® test) for detection of premature rupture of fetal membranes , 2012, Archives of Gynecology and Obstetrics.

[5]  V. Tsatsaris,et al.  [Comparison of two bedside tests performed on cervicovaginal fluid to diagnose premature rupture of membranes]. , 2011, Journal de gynecologie, obstetrique et biologie de la reproduction.

[6]  K. Kwek,et al.  Comparative analysis of insulin-like growth factor binding protein-1 (IGFBP-1), placental alpha-microglobulin-1 (PAMG-1) and nitrazine test to diagnose premature rupture of membranes in pregnancy , 2010, Journal of perinatal medicine.

[7]  R. Romero,et al.  528: A role for placental alpha-microglobulin-1 in the identification of women with a sonographic short cervix at risk for spontaneous rupture of membranes , 2009 .

[8]  R. Romero,et al.  The clinical significance of a positive Amnisure test™ in women with term labor with intact membranes , 2009, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[9]  E. Norwitz,et al.  Measurement of Placental Alpha-Microglobulin-1 in Cervicovaginal Discharge to Diagnose Rupture of Membranes , 2007, Obstetrics and gynecology.

[10]  L. Cousins,et al.  AmniSure placental alpha microglobulin-1 rapid immunoassay versus standard diagnostic methods for detection of rupture of membranes. , 2005, American journal of perinatology.

[11]  J. Kuhle,et al.  Placental α-microglobulin-1 to detect uncertain rupture of membranes in a European cohort of pregnancies , 2011, Archives of Gynecology and Obstetrics.